Skip to main content
RLMDRelmada Therapeutics—

Relmada Therapeutics (RLMD) Q2 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+44.4% vs estimateEPS -$0.11 vs -$0.20 est

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q2 2026

Key numbers

Adjusted EPS
-$0.11
Estimate
-$0.20
Surprise
+44.4%

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Relmada Therapeutics (RLMD) reported a narrower loss than forecast — adjusted EPS of -$0.11 against the -$0.20 estimate (a 44.4% beat on a still-unprofitable quarter).

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › RLMD › Earnings › Q2 2026 earnings